ATE465750T1 - Verwendung eines replikationdefizienten pockenvirusvektors zur erhöhung der cd4+ t-zell- immunantwort gegen antigen - Google Patents

Verwendung eines replikationdefizienten pockenvirusvektors zur erhöhung der cd4+ t-zell- immunantwort gegen antigen

Info

Publication number
ATE465750T1
ATE465750T1 AT01965468T AT01965468T ATE465750T1 AT E465750 T1 ATE465750 T1 AT E465750T1 AT 01965468 T AT01965468 T AT 01965468T AT 01965468 T AT01965468 T AT 01965468T AT E465750 T1 ATE465750 T1 AT E465750T1
Authority
AT
Austria
Prior art keywords
replication
antigen
deficiency
increase
immune response
Prior art date
Application number
AT01965468T
Other languages
English (en)
Inventor
Adrian Hill
Helen Mcshane
Sarah Gilbert
William Reece
Joerg Schneider
Original Assignee
Oxxon Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxxon Therapeutics Ltd filed Critical Oxxon Therapeutics Ltd
Application granted granted Critical
Publication of ATE465750T1 publication Critical patent/ATE465750T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01965468T 2000-09-21 2001-09-13 Verwendung eines replikationdefizienten pockenvirusvektors zur erhöhung der cd4+ t-zell- immunantwort gegen antigen ATE465750T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0023203.3A GB0023203D0 (en) 2000-09-21 2000-09-21 Vaccination method
PCT/GB2001/004116 WO2002024224A2 (en) 2000-09-21 2001-09-13 Use of replication-deficient poxvirus vector to boost cd4+ t cell immune response to antigen

Publications (1)

Publication Number Publication Date
ATE465750T1 true ATE465750T1 (de) 2010-05-15

Family

ID=9899889

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01965468T ATE465750T1 (de) 2000-09-21 2001-09-13 Verwendung eines replikationdefizienten pockenvirusvektors zur erhöhung der cd4+ t-zell- immunantwort gegen antigen

Country Status (10)

Country Link
US (1) US20040018177A1 (de)
EP (1) EP1320379B8 (de)
JP (1) JP5102930B2 (de)
AT (1) ATE465750T1 (de)
AU (2) AU8610901A (de)
CA (1) CA2422094C (de)
DE (1) DE60141969D1 (de)
ES (1) ES2345604T3 (de)
GB (2) GB0023203D0 (de)
WO (1) WO2002024224A2 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
US20030138454A1 (en) * 1997-06-09 2003-07-24 Oxxon Pharmaccines, Ltd. Vaccination method
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
PL212047B1 (pl) 2000-11-23 2012-08-31 Bavarian Nordic As Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
EP1450854A2 (de) * 2001-11-30 2004-09-01 Isis Innovation Limited Impfstoff
NZ536592A (en) 2002-04-19 2007-01-26 Bavarian Nordic As Modified vaccinia virus ankara for the vaccination of neonates
US20050123561A1 (en) * 2002-05-20 2005-06-09 Mitsuo Honda Radio lan access authentication system
JP2005537793A (ja) 2002-09-05 2005-12-15 バヴァリアン・ノルディック・アクティーゼルスカブ 無血清条件下で初代細胞を培養する方法及びウイルスを増幅させる方法
DE10249390A1 (de) * 2002-10-23 2004-05-13 Ruprecht-Karls-Universität Heidelberg Rekombinante MVA-Stämme als potentielle Impfstoffe gegen P.falciparum-Malaria
US20050175627A1 (en) * 2003-09-24 2005-08-11 Oxxon Therapeutics Ltd. HIV pharmaccines
GB2421025A (en) * 2004-12-09 2006-06-14 Oxxon Therapeutics Ltd HSV vaccination vectors
WO2006120474A2 (en) * 2005-05-13 2006-11-16 Oxxon Therapeutics Ltd Compositions for inducing an immune response against tumor antigens
EP2125868B1 (de) * 2007-02-28 2015-06-10 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Brachyurie-polypeptide und verwendungsverfahren
MX2017002890A (es) 2014-09-03 2017-11-13 Bavarian Nordic As Métodos y composiciones para potenciar respuestas inmunitarias.
HUE065565T2 (hu) 2014-09-03 2024-06-28 Bavarian Nordic As Módszerek és készítmények filovírus fertõzés elleni védõ immunitás elõidézésére
ES2865150T3 (es) 2014-09-26 2021-10-15 Beth Israel Deaconess Medical Ct Inc Métodos y composiciones para inducir inmunidad protectora contra la infección por el virus de la inmunodeficiencia humana
CN105753989A (zh) * 2014-12-15 2016-07-13 牛津疫苗医学生物科技（英国）有限公司 人工多抗原融合蛋白及其制备和应用
US10881725B2 (en) 2016-01-29 2021-01-05 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara (MVA) equine encephalitis virus vaccine
JP7250520B2 (ja) 2016-04-13 2023-04-03 ヤンセン ファーマシューティカルズ，インコーポレーテッド 組換えアルテリウイルスレプリコン系およびその使用
EP3484507A1 (de) 2016-07-15 2019-05-22 Janssen Vaccines & Prevention B.V. Verfahren und zusammensetzungen zur induzierung von schützender immunität gegen eine marburg-virus-infektion
CA3035759A1 (en) 2016-09-02 2018-03-08 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
KR102718353B1 (ko) 2016-10-17 2024-10-15 얀센 파마슈티칼즈, 인코포레이티드 재조합 바이러스 레플리콘 시스템 및 그의 용도
JP7788787B2 (ja) 2016-12-05 2025-12-19 ヤンセン ファーマシューティカルズ，インコーポレーテッド 遺伝子発現増強のための組成物および方法
US11173204B2 (en) 2017-04-06 2021-11-16 Janssen Vaccines & Prevention B.V. MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen
US20190022212A1 (en) 2017-07-21 2019-01-24 Beth Israel Deaconess Medical Center, Inc. Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human
US20190083620A1 (en) 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
US11020476B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
CN111741766A (zh) 2017-12-19 2020-10-02 杨森科学爱尔兰无限公司 用于诱导针对乙型肝炎病毒(hbv)的免疫应答的方法和组合物
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
WO2019143949A2 (en) 2018-01-19 2019-07-25 Synthetic Genomics, Inc. Induce and enhance immune responses using recombinant replicon systems
KR20210074314A (ko) 2018-10-08 2021-06-21 얀센 파마슈티칼즈, 인코포레이티드 생체치료제의 투여를 위한 알파바이러스 기반 레플리콘
TW202110476A (zh) 2019-05-22 2021-03-16 荷蘭商傑森疫苗防護公司 於接受抗反轉錄病毒治療之個體中誘發抗人類免疫缺乏病毒感染之免疫反應的方法
EP3928789A1 (de) 2020-06-24 2021-12-29 Consejo Superior de Investigaciones Científicas (CSIC) Mva-basierter impfstoff gegen covid-19 exprimierende sars-cov-2-antigene
WO2021260065A1 (en) 2020-06-24 2021-12-30 Consejo Superior De Investigaciones Científicas (Csic) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
CN116367854A (zh) 2020-07-08 2023-06-30 杨森科学爱尔兰无限公司 针对hbv的rna复制子疫苗
WO2022269003A1 (en) 2021-06-23 2022-12-29 Consejo Superior De Investigaciones Cientificas MVA-BASED VACCINE EXPRESSING A PREFUSION-STABILIZED SARS-CoV-2 S PROTEIN
EP4108257A1 (de) 2021-06-23 2022-12-28 Consejo Superior De Investigaciones Científicas Impfstoff auf mva-basis gegen covid-19, der ein präfusionsstabilisiertes sars-cov-2-s-protein exprimiert
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses
EP4316514A1 (de) 2022-08-03 2024-02-07 Consejo Superior de Investigaciones Científicas (CSIC) Vektoren auf mva-basis und ihre verwendung als impfstoff gegen sars-cov-2
WO2024063788A1 (en) * 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
JP2025533541A (ja) * 2022-09-23 2025-10-07 ビオンテック・ソシエタス・エウロパエア 肝病期抗原の送達のための組成物及び関連方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
US7094408B2 (en) * 2000-04-28 2006-08-22 The United States Of America As Represented By The Department Of Health And Human Services Immunogenicity using a combination of DNA and vaccinia virus vector vaccines
DK1282702T3 (da) * 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf

Also Published As

Publication number Publication date
JP2004509149A (ja) 2004-03-25
ES2345604T3 (es) 2010-09-28
AU2001286109B2 (en) 2006-12-14
WO2002024224A3 (en) 2002-06-13
GB2384709B (en) 2005-05-04
AU8610901A (en) 2002-04-02
CA2422094C (en) 2011-04-19
EP1320379A2 (de) 2003-06-25
DE60141969D1 (de) 2010-06-10
EP1320379B1 (de) 2010-04-28
CA2422094A1 (en) 2002-03-28
GB0308955D0 (en) 2003-05-28
JP5102930B2 (ja) 2012-12-19
US20040018177A1 (en) 2004-01-29
GB2384709A (en) 2003-08-06
WO2002024224A2 (en) 2002-03-28
EP1320379B8 (de) 2010-06-02
GB0023203D0 (en) 2000-11-01

Similar Documents

Publication Publication Date Title
ATE465750T1 (de) Verwendung eines replikationdefizienten pockenvirusvektors zur erhöhung der cd4+ t-zell- immunantwort gegen antigen
CY1105594T1 (el) Παραλλαγη τροποποιημενου ιου vaccinia ankara
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
BR9814487A (pt) "vacina"
DE60110822D1 (de) Zubereitung zur immunisierung gegen den aids-virus
EP1504112A4 (de) Entwicklung einer vakzine zur prävention von infektionen mit dem filovirus bei primaten
PT677114E (pt) Virus da variola suina recombinante
DK0669133T3 (da) Multipotente paramunitetsindicerede midler baseret på kombinationer af koppeviruskomponenter, fremgangsmådde til fremstilling deraf og deres anvendelse som lægemidler
MXPA05005549A (es) Virus recombinante de viruela que comprende al menos dos promotores ati de viruela de vaca.
MX2020009541A (es) Virus vaccinia oncolitico que expresa bloqueo de punto de control inmunologico para inmunoterapia de cancer.
DK1425404T3 (da) Vaccinia-MVA-E3L-mutanter og anvendelse deraf
EA200701633A1 (ru) Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1
WO2003076591A3 (en) Compositions and methods for generating an immune response
EA200700496A1 (ru) Инактивированная полиомиелитная вакцина, полученная из штамма сейбина вируса полиомиелита
DK1404852T3 (da) Ekspression af gener i modificeret vacciniavirus Ankara ved anvendelse af kokoppe-ATI-promotoren
ATE471990T1 (de) Transkutane immunisierung gegen papillomavirus mit virusähnlichen papillomaviruspartikeln
DK0964697T3 (da) Terapeutiske anvendelser af antigener eller epitoper knyttet til forringet cellulær peptidprocessering, f.eks. eksprimeret på RMA-S-celler transficeret med et B7-1-gen
AR124384A1 (es) Parapoxvirus modificado que tiene inmunogenicidad aumentada
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
UA100836C2 (ru) Применение модифицированного вируса осповакцины анкара (mva) для быстрой индукции иммунитета против поксвирусных или других инфекционных агентов
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
SE9600436D0 (sv) Vaccine against hantavirus
ATE310807T1 (de) Trennung eines humanen retrovirus
ATE324450T1 (de) Polypeptid, das neutralisierende antikörper gegen hiv induziert
NO20042124L (no) Thymosinforsterkning ved genetisk immunisering